Bedrijfsoverzicht
Larimar Therapeutics, Inc. is a clinical-stage biotechnology entity dedicated to advancing treatments for rare diseases through the application of its proprietary cell penetrating peptide technology platform. Operating within the healthcare sector and specifically the biotechnology industry, the company focuses on high-risk, high-reward research and development phases that are characteristic of pre-commercial therapeutic discovery. The organization currently employs 71 individuals and holds a market capitalization of $503.83M, while reported annual revenue and price-to-sales figures are not available in the current financial dataset. The substantial market cap relative to the absence of reported sales revenue indicates that the company's valuation is primarily driven by the potential of its pipeline assets, specifically its lead product candidate CTI-1601, which is undergoing Phase 2 OLE clinical trials for Friedreich's ataxia, rather than current commercial performance. This positioning places the firm in a developmental stage where investor capital is essential to fund ongoing clinical operations before generating significant commercial revenue streams.
Financiële gezondheid
The company reported net income of $-165,672,992 and EBITDA of $-172,147,008 over the trailing twelve months, while revenue and price-to-sales metrics are listed as N/A. The significant gap between the reported net income and EBITDA figures reveals a cost structure heavily influenced by non-operating expenses or specific financial charges that impact the bottom line more severely than core operating cash flows. Free cash flow stands at $-53,473,624, indicating that the company is consuming cash to fund its research and development activities rather than generating excess liquidity for shareholder distributions. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure typical for early-stage biotechnology firms that have not yet achieved commercial scale or profitability. Despite the negative earnings, the company maintains a cash balance of $136.85M against total debt of $4.07M, resulting in a debt-to-equity ratio of 5.21 which suggests a highly leveraged balance sheet in the context of negative equity but manageable absolute debt levels. The current ratio is 2.19, indicating that the company holds sufficient liquid assets to cover its short-term obligations more than twice over, providing a buffer for operational continuity. Return on Equity is -132.6% and Return on Assets is -62.3%, metrics that reflect the dilutive nature of losses relative to the equity base and asset base, respectively, highlighting that management is currently prioritizing growth over immediate return generation.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the absence of net income, while the forward P/E ratio is reported at -2.69. The negative forward P/E implies that the market is pricing in a period of continued earnings contraction or significant investment outlays before the company can achieve positive earnings per share. The price-to-book ratio is 5.16, suggesting that the market values the company at more than five times its book value, which often reflects the high intangible value of intellectual property and clinical potential in biotechnology rather than tangible asset backing. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -2.15, further illustrate that traditional profitability-based valuation models are not applicable to the company's current financial state. The 52-week high is $6.42 and the 52-week low is $1.73; without a specific current share price provided in the dataset, the range defines the volatility envelope within which the stock has traded over the last year. The beta value is 1.02, indicating that the stock's price volatility is slightly higher than the broader market, moving in tandem with general market fluctuations while exhibiting a modestly increased sensitivity to market movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, precluding a direct comparison of growth rates between earnings and revenue in the current reporting period. Because the company has not yet generated positive earnings or consistent revenue growth data, a traditional analysis of earnings growing faster or slower than revenue is not applicable to this clinical-stage entity. Larimar Therapeutics does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all available capital to reinvest into its research pipeline and clinical trials. Consequently, the overall growth and income profile is defined entirely by the potential future realization of its asset pipeline rather than current cash distributions or historical growth metrics. The absence of dividend income and reported growth figures underscores the company's focus on long-term therapeutic development rather than short-term shareholder yield.